Dr Reddy Laboratories Limited
Dr. Reddy’s Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
Key Business segments
- Global Generics Segment (~83% of revenues in FY22)
- Pharmaceutical Services & Active Ingredients (PSAI) (14% of revenues in FY22)
- Proprietary Products & Others (~2% of revenues)
Shareholding Pattern
-PUBLIC GROUP
-PROMOTER GROUP
Financial Summary
| Particulars | Mar-23 | Mar-24 | Mar-25 |
| Sales | 24,670 | 28,011 | 32,644 |
| Sales Growth % | 14.50% | 13.54% | 16.54% |
| Expenses | 18,200 | 20,078 | 24,097 |
| Operating Profit | 6,470 | 7,933 | 8,547 |
| OPM % | 26% | 28% | 26% |
| Net Profit | 4,507 | 5,578 | 5,725 |
| EPS in Rs | 54.14 | 66.87 | 67.77 |
Synopsis of Financials
- FY25 consolidated revenues: ₹32,554 crores ($3.8bn), YoY growth 17%.
- Q4FY25 revenues: ₹8,506 crores ($996mn), YoY growth 20%, sequential growth 2%.
- EBITDA: Crossed $1bn for the first time; FY25 EBITDA at ₹9,213 crores ($1.1bn), YoY growth 11%; Q4 EBITDA ₹2,475 crores ($290mn), YoY growth 32%.
- EBITDA margin: Q4 at 29.1% (+267bps YoY), FY25 at 28.3% (down 143bps YoY).
- PAT (attributable to equity holders): FY25 ₹5,655 crores, YoY growth 2%, margin at 17%.
- EPS: ₹19.1 for Q4, ₹68.1 for FY25.
Final Outlook
Dr. Reddy’s showcases robust capital efficiency, with a high and stable ROCE of 27%, outperforming many peers. Despite this, FY24 saw a rise in its cash conversion cycle (201 to 256 days) and inventory days (232 to 283), hinting at operational inefficiencies in inventory and payables management. However, stable debtor days and strong profitability indicate resilience. Strategic investments and consistent innovation in high-margin markets like biosimilars and generics continue to support long-term growth.
With strong capital returns, a sound balance sheet, and a global expansion strategy, Dr. Reddy’s remains a solid long-term bet in the pharma sector. Investors should watch inventory and working capital trends, but the company’s innovation-driven approach and international presence make it a valuable portfolio addition for 2–3 year holding.
Dr-Reddy-Laboratories-Limited-PDF-Report